Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 5/20 | 0.34 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15220324 | 0.89 | KMT2A (0.38) | MAPK1KMT2AALDH1A1HPGDYEATS4 | |
| SCHEMBL16440503 | 0.83 | MAPK1 (0.37) | MAPK1KMT2AALDH1A1YEATS4RAB9A | |
| SCHEMBL18532092 | 0.82 | KMT2A (0.34) | MAPK1KMT2AALDH1A1HPGDYEATS4 | |
| SCHEMBL15220425 | 0.82 | ALDH1A1 (0.40) | MAPK1KMT2AALDH1A1HPGDMAPT | |
| SCHEMBL20963121 | 0.82 | ALDH1A1 (0.33) | MAPK1KMT2AALDH1A1HPGDMAPT | |
| SCHEMBL12233069 | 0.82 | ALDH1A1 (0.33) | MAPK1KMT2AALDH1A1HPGDMAPT | |
| SCHEMBL11982808 | 0.82 | ALDH1A1 (0.36) | MAPK1KMT2AALDH1A1HPGDMAPT | |
| SCHEMBL12648423 | 0.81 | DAO (0.42) | MAPK1KMT2AALDH1A1HPGDMAPT | |
| SCHEMBL11892122 | 0.80 | MAPT (0.41) | MAPK1KMT2AALDH1A1HPGDYEATS4 | |
| SCHEMBL1522621 | 0.79 | YEATS4 (0.37) | MAPK1KMT2AYEATS4RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-11209437-B2 | Fluorescent probe and preparation method and use thereof | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY (CN) | 2021-12-28 | — | — | US | disclosed |
| US-11208527-B2 | Photoactive macromolecules and uses thereof | BECKMAN COULTER, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| WO-2020102098-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10441659-B2 | Lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2019-10-15 | — | — | US | disclosed |
| US-10364267-B2 | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190187144-A1 | FLUORESCENT PROBE AND PREPARATION METHOD AND USE THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20090105262-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | ALLACCEM, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM, INC. | 2008-11-06 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080221167-A1 | for controlling insects and/or arachnids | BAYER CROPSCIENCE AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221167-A1 | for controlling insects and/or arachnids | BAYER CROPSCIENCE AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080167472-A1 | TUNABLE PHENYLACETYLENE HOSTS | STATE OF OREGON ACTING BY AND THROUGH THE STATE | 2008-07-10 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105262-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | PAICS, KRTCAP2, OSTC | MAPK1 4024/4885KMT2A 2271/4885ALDH1A1 2132/4885 |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | PAICS, SLC16A8, CAD | MAPK1 3573/4885KMT2A 855/4885ALDH1A1 653/4885 |
| US-20190187144-A1 | FLUORESCENT PROBE AND PREPARATION METHOD AND USE THEREOF | HNRNPF, HNRNPUL2, RAB5IF | MAPK1 4517/4885KMT2A 4751/4885ALDH1A1 3152/4885 |
| US-10364267-B2 | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | NR1H4, GPBAR1, SLC10A1 | MAPK1 2365/4885KMT2A 4041/4885ALDH1A1 2765/4885 |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | C3AR1, C5AR1, C5AR2 | MAPK1 1284/4885KMT2A 3598/4885ALDH1A1 3370/4885 |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | MAPK1 428/4885KMT2A 232/4885ALDH1A1 1314/4885 |
| US-10441659-B2 | Lipids for therapeutic agent delivery formulations | LIPA, SGMS2, SGMS1 | MAPK1 4688/4885KMT2A 4227/4885ALDH1A1 3744/4885 |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | BMP2, BMP1, BMP6 | MAPK1 2825/4885KMT2A 1766/4885ALDH1A1 3387/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | MAPK1 2900/4885KMT2A 3734/4885ALDH1A1 2109/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | MAPK1 280/4885KMT2A 1079/4885ALDH1A1 4191/4885 |
| US-20080167472-A1 | TUNABLE PHENYLACETYLENE HOSTS | AADAC, PML, AHR | MAPK1 4706/4885KMT2A 1805/4885ALDH1A1 1062/4885 |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MAPK1 1647/4885KMT2A 4441/4885ALDH1A1 1972/4885 |
| US-11209437-B2 | Fluorescent probe and preparation method and use thereof | HNRNPF, HNRNPUL2, RAB5IF | MAPK1 4517/4885KMT2A 4751/4885ALDH1A1 3152/4885 |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | PKD1, VHL, PKD2 | MAPK1 3843/4885KMT2A 2822/4885ALDH1A1 1058/4885 |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | MAPK1 3043/4885KMT2A 1375/4885ALDH1A1 2781/4885 |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | MAPK1 1612/4885KMT2A 52/4885ALDH1A1 796/4885 |
| US-20080221167-A1 | for controlling insects and/or arachnids | CRYAB, DDC, DDT | MAPK1 4695/4885KMT2A 290/4885ALDH1A1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.